Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Non-Current Debt (2022 - 2025)

TScan Therapeutics (TCRX) has disclosed Non-Current Debt for 4 consecutive years, with $32.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 1.44% to $32.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.5 million through Dec 2025, up 1.44% year-over-year, with the annual reading at $32.5 million for FY2025, 1.44% up from the prior year.
  • Non-Current Debt for Q4 2025 was $32.5 million at TScan Therapeutics, roughly flat from $32.4 million in the prior quarter.
  • The five-year high for Non-Current Debt was $32.5 million in Q4 2025, with the low at $20.1 million in Q2 2024.
  • Average Non-Current Debt over 4 years is $29.2 million, with a median of $29.6 million recorded in 2023.
  • The sharpest move saw Non-Current Debt tumbled 32.33% in 2024, then skyrocketed 60.58% in 2025.
  • Over 4 years, Non-Current Debt stood at $29.3 million in 2022, then decreased by 8.84% to $26.7 million in 2023, then increased by 20.12% to $32.1 million in 2024, then rose by 1.44% to $32.5 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $32.5 million, $32.4 million, and $32.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.